Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.55 |
| ▸ | DPP4 | P27487 | 3/20 | 0.55 |
| ▸ | ESR1 | P03372 | 11/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10914223 | 0.82 | ANPEP (0.50) | ANPEPDPP4ESR1ESR2MAOA | |
| SCHEMBL24710720 | 0.82 | ANPEP (0.51) | ANPEPDPP4ESR1ESR2MAOA | |
| SCHEMBL6307015 | 0.81 | MEN1 (0.56) | ANPEPDPP4ESR1ESR2MAOA | |
| SCHEMBL6307012 | 0.81 | MEN1 (0.56) | ANPEPDPP4ESR1ESR2MAOA | |
| SCHEMBL1686814 | 0.81 | ESR1 (0.50) | ESR1ESR2MEN1KMT2AAPP | |
| SCHEMBL17300647 | 0.79 | BCL2 (0.41) | ANPEPDPP4MEN1KMT2ATDP1 | |
| SCHEMBL6308700 | 0.79 | ESR1 (0.48) | ANPEPDPP4ESR1ESR2MAOA | |
| SCHEMBL6308693 | 0.79 | ESR1 (0.48) | ANPEPDPP4ESR1ESR2MAOA | |
| SCHEMBL317136 | 0.79 | MEN1 (0.53) | ANPEPDPP4ESR1ESR2MAOA | |
| SCHEMBL2665475 | 0.78 | MAOA (0.50) | MAOAMAOBAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732133-B2 | Process for producing a three-dimensional object | EOS GMBH ELECTRO OPTICAL SYSTEMS (DE) | 2023-08-22 | — | — | US | disclosed |
| US-20200172527-A1 | BENZOXAZINONE DERIVATIVES USEFUL AS HERBICIDES | REDAG CROP PROT LTD (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200140706-A1 | PROCESS FOR PRODUCING A THREE-DIMENSIONAL OBJECT | EOS GMBH ELECTRO OPTICAL SYSTEMS (DE) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172527-A1 | BENZOXAZINONE DERIVATIVES USEFUL AS HERBICIDES | CBR3, CBR1, CYP4X1 | ANPEP 3938/4885DPP4 924/4885ESR1 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.